$14.400
+0.243 (+1.69%)終値時点
BLSM のニュース
BLSM のイベント
BlossomHill Presents Preclinical Data on BH-501284 at AACR Conference
BlossomHill Therapeutics announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research, AACR, Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, taking place September 25-28, 2026, in San Diego, CA. Presentation highlights: BH-501284 exhibited potent and prolonged activity across a broad range of KRAS mutations; BH-501284 showed deep and durable antitumor activity across multiple preclinical KRAS-mutant tumor models; BH-501284 demonstrated deeper and more durable tumor regression than tricomplex RAS inhibitors; BH-501284 also demonstrated the potential to combine with an anti-PD-1 treatment.
Middle East War Influences Energy Prices and Markets
In the week ahead, the war in the Middle East will continue to dictate energy prices and financial markets as major central banks have hiked rates to combat inflation. Meanwhile, calls to slow AI advancement could impact the sector that has supported global stocks, credit issuance, and commodities. These matters, in addition to trade, are expected to be leading focal points in the highly anticipated meeting between U.S. and Chinese Presidents Trump and Xi.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Berkshire Hathawaynamed Warren Buffett as Chairman Emeritus and elected Howard Buffett as Chairman of the BoardApple'siPhone 18 Pro and Pro Max began hitting stores, though its foldable iPhone Duo will not be available for sale until October 23On Holdingannounced its entrance into the soccer market with "a major talent investment" into star Kylian Mbappe, a former brand ambassador for NikeSteelmakers Nucorand Steel Dynamicsboth guided Q3 earnings below consensusShares of U.S. and European carmakers were under pressure after Volkswagencut its operating-margin forecast2. WALL STREET CALLS:Wells Fargo downgraded Netflixto a sell-equivalent Underweight, calling the company's engagement trends "worrying"BTIG upgraded Etsyafter pullback, sees 24% upsideAccenturedowngraded to Neutral at Guggenheim after 52% reboundCiti upgraded StubHubto Buy on "robust" Q3 trendsYetiupgraded to Buy at Stifel after analyst day meeting3. AROUND THE WEB:Allspring Global Investments, acquired from Wells Fargoby GTCR and Reverence Capital in 2021 for $2.1B, is exploring a sale at a potential valuation of $4B, FT reportsMedia reports indicate the CEOs of OpenAI, Nvidiaand JPMorganare among executives slated to attend the Trump-Xi state dinnerNestlesaid it is assessing options for its Russian unit after Russian President Vladimir Putin ordered the company's Russian assets to be placed under temporary administration, WSJ reportsMetaCEO Mark Zuckerberg, NvidiaCEO Jensen Huang, and Teslaand SpaceX'sElon Musk recently spoke with President Trump and successfully stalled an AI regulatory plan proposed by Demis Hassabis, WSJ saysHondaintends to accelerate mass production of its next-generation hybrid vehicles by multiple months, Nikkei says4. MOVERS:Mistrasadvanced after announcing it will be acquired by H.I.G. Capital for $20.35 per share in cashCooper Companiesrose after Jana Partners urged the company to initiate an external search for its CEOXenonfell after pausing enrollment for its MDD and BPD studiesArray Technologiesdeclined after UBS downgraded the stock to NeutralFluenceclosed lower after Jefferies downgraded the stock to Hold5. EARNINGS/GUIDANCE:BlossomHill Therapeuticsreported Q2 results, with EPS lower year-over-yearSolowinreported results for FY26Rexford Industrialreaffirmed its outlook for FY26Progressivereported August EPSAutoZoneto report Q4 results on September 22INDEXES:The Dow fell 95.40, or 0.18%, to 51,682.64, the Nasdaq gained 104.25, or 0.39%, to 26,522.55, and the S&P 500 advanced 12.74, or 0.17%, to 7,650.50.
Stocks Drop as Treasury Yields Rebound
Stocks swung lower on Friday as Treasury yields rebounded and rekindled concerns of a deteriorating macroeconomic backdrop. The yield on the 10-year Treasury note rebounded above the 5% threshold as persistent uncertainty over Middle Eastern oil supply drove fuel and natural gas prices to rise. The prolonged threat of energy inflation has already impacted underlying consumer prices, driving the Fed to hike rates this week, while most FOMC members see the need for another hike.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Berkshire Hathawaynamed Warrenand elected Howard Buffett as Chairman of the BoardApple'siPhone 18 Pro and Pro Max, though its foldable iPhone Duo will not be available for sale until October 23On Holdingannounced its entrance into the soccer market withinto star Kylian Mbappe, a former brand ambassador for NikeSteelmakers Nucorand Steel Dynamicsbelow consensusThe FCCrequest to allow foreign investors to back its acquisition of Warner Bros Discovery, but said they could not hold voting stock2. WALL STREET CALLS:Wells FargoNetflixto a sell-equivalent Underweight, calling the company's engagement trends "worrying"BTIGEtsyafter pullback, sees 24% upsideAccentureto Neutral at Guggenheim after 52% reboundCitiStubHubto Buy on "robust" Q3 trendsYetito Buy at Stifel after analyst day meeting3. AROUND THE WEB:Allspring Global Investments, acquired from Wells Fargo (WFC) by GTCR and Reverence Capital in 2021 for $2.1B, is exploring a sale at a potential valuation of $4B, FT reportsSoftBankhas increased its loan backed by Armshares by $5B to $25B, Bloomberg saysNestlesaid it is assessing options for its Russian unit after Russian President Vladimir Putin ordered the company's Russian assets to be placed under temporary administration, WSJ reportsMetaCEO Mark Zuckerberg, NvidiaCEO Jensen Huang, and Teslaand SpaceX'sElon Musk recently spoke with President Trump and successfully stalled an AI regulatory plan proposed by Demis Hassabis, WSJ saysHondaintends to accelerate mass production of its next-generation hybrid vehicles by multiple months, Nikkei says4. MOVERS:Mistrasgains after announcing it will be acquired by H.I.G. Capital forin cashCooper Companiesincreases after Jana Partners urged the company tofor its CEOXenondeclines in New York afterfor its MDD and BPD studiesArray Technologiesfalls after UBSthe stock to NeutralFluencelower after Jefferiesthe stock to Hold5. EARNINGS/GUIDANCE:BlossomHill Therapeutics, with EPS lower year-over-yearSolowinRexford Industrialfor FY26ProgressiveAutoZoneon September 22INDEXES:Near midday, the Dow was down 223.14, or 0.43%, to 51,554.90, the Nasdaq was down 37.31, or 0.14%, to 26,380.99, and the S&P 500 was down 16.67, or 0.22%, to 7,621.09.
BlossomHill Therapeutics Achieves Significant Progress
"We've achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter," said Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill Therapeutics. "In April, we presented our first preclinical data from our pseudo-irreversible pan-KRAS inhibitor BH-501284, built on a novel chemical scaffold, at AACR where we highlighted the sustained target engagement leading to tumor regression at low dose levels. At ASCO in early June we presented the preliminary safety, PK and antitumor activities of BH-30643 in Phase 1 dose escalation of the SOLARA trial, along with the initial efficacy data in C797S-positive NSCLC. More recently we announced that BH-30643 received Fast Track designation, an important regulatory milestone that reflects the FDA's recognition of the potential for this molecule. We also presented encouraging safety data and early signs of anti-leukemic activity observed with BH-30236, our novel macrocyclic CLK inhibitor, both as a monotherapy and in combination with venetoclax, at EHA in the middle of June. We are now looking forward to our end-of-phase 1 meeting with the FDA later this year."
BlossomHill Updates BH-30643 Clinical Trial Data
BlossomHill Therapeutics announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancerm or NSCLC, patients with secondary epidermal growth factor receptor resistance mutations such as EGFR C797S. The data were highlighted in a mini-oral presentation at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul, South Korea. In patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, BH-30643 demonstrated a 45% objective response rate and an 88% disease control rate. At the time of efficacy follow-up, 63% of patients remained on treatment with a median follow-up of 6.9 months. BH-30643 also demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events. Encouraging anti-tumor activity was observed in patients with C797S-positive resistance. Among 40 patients with EGFR C797S-positive resistance to prior EGFR inhibitor treatment, with or without concurrent T790M, 18 patients achieved a confirmed or ongoing unconfirmed partial response, representing an ORR of 45%. The DCR was 88%, and 25 patients remained on treatment at the time of efficacy follow-up. Median follow-up was 6.9 months. Activity was observed across a clinically heterogeneous, previously treated population. Patients had received a median of two prior lines of therapy; 98% had received prior osimertinib, 53% had received prior chemotherapy and/or an antibody-drug conjugate, and 53% had a history of brain metastases. 35% of patients had concurrent T790M. BH-30643 demonstrated a favorable safety profile at expansion doses. Among 174 patients treated at doses of 40 mg, 50 mg and 60 mg twice daily, treatment-related dose reductions and discontinuations occurred in 9% and 3% of patients, respectively. EGFR wild-type-associated treatment-related adverse events were primarily Grade 1. The most common treatment-related adverse event was bilirubin elevation, which was generally asymptomatic and predominantly unconjugated, consistent with UGT1A1 inhibition by BH-30643. Development of BH-30643 is continuing across multiple EGFR-mutant populations. Expansion cohorts are evaluating on-target resistance mutations, targeted therapy-naive patients and BH-30643 in combination with chemotherapy. BlossomHill plans to initiate a global Phase 2 study targeting EGFR C797S-positive NSCLC in Q1 2027.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。